Skip to main content
logo
Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,683,000
-12,000 (-0.71%)
At close: Jan 2, 2026

Revenue by Geography

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Domestic Revenue
144.43B135.18B
Log In
Log In
Log In
Upgrade
Europe Revenue
3.06T2.96T
Log In
Log In
Log In
Upgrade
USA Revenue
1.55T1.17T
Log In
Log In
Log In
Upgrade
Other Geographic Revenue
278.82B274.75B
Log In
Log In
Log In
Upgrade

Revenue Breakdown

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Contract Development and Manufacturing Organization (CDMO) Revenue
3.01T
Log In
Log In
Log In
Upgrade
Biopharmaceutical Development and Commercialization Revenue
1.54T
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Product Revenue
4.79T4.17T
Log In
Log In
Log In
Upgrade
Other Revenue
238.67B382.25B
Log In
Log In
Log In
Upgrade

EBIT

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Contract Development and Manufacturing Organization (CDMO) Operating Profit
1.12T
Log In
Log In
Log In
Upgrade
Biopharmaceutical Development and Commercialization Operating Profit
200.69B
Log In
Log In
Log In
Upgrade
Updated Jun 30, 2025. Data Source: Fiscal.ai.